{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009128","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.540283+00:00","generated_at":"2026-06-05T01:30:48.375346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lipocine reports FY2023 net loss $16.4M; signs TLANDO license deal with Verity Pharma for $11M upfront","bullets":["Net loss $16.4M ($3.14 diluted EPS) in 2023 vs $10.8M loss in 2022; revenue reversal of $2.9M from Antares termination.","Entered exclusive license with Verity Pharma for TLANDO in U.S./Canada; received $7.5M of $11M upfront, up to $259M milestones, 12-18% royalties.","Cash $22.0M at 2023 year-end; subsequent $7.5M from Verity brings pro-forma cash to ~$29.5M.","LPCN 1154 oral brexanolone: positive PK bridge study; pivotal study starts Q1'24, NDA filing expected Q4'24.","LPCN 1148 Phase 2 POC met primary endpoint for decompensated cirrhosis; fewer HE events, symptom improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009128","json":"https://secwatch.observer/filing/0001493152-24-009128.json","markdown":"https://secwatch.observer/filing/0001493152-24-009128.md","text":"https://secwatch.observer/filing/0001493152-24-009128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224009128/0001493152-24-009128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224009128/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:30:48.375346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6de3160df5d2d14ec16ca916f9b1a39e69fcdb59","claim":"Lipocine Inc. reported the year ended December 31, 2023 results: revenue $2.9 million, net income net loss of $16.4 million, EPS ($3.14) per diluted share.","evidence_excerpt":"per diluted share, for the year ended December 31, 2022. During 2023 Lipocine recognized a non-cash minimum guaranteed royalties reversal of variable consideration revenue of $2.9 million related to the termination of the Antares License Agreement. The reversal of revenue is due to the fact that, as a result of the termination of the license agreement, the Company","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224009128/0001493152-24-009128-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$2.9 million"},{"label":"Net income","value":"net loss of $16.4 million"},{"label":"EPS","value":"($3.14) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}